NeuroPace adds Lisa Andrade to its Board of Directors

– USA, CA –  NeuroPace, Inc., (Nasdaq: NPCE) a medical technology company dedicated to transforming the lives of people suffering from epilepsy, today announced the addition of Lisa Andrade to its Board of Directors, effective November 1, 2021, bringing over 25 years of experience in both large and early-stage MedTech, software and technology companies.

“We are excited to welcome Lisa to our Board of Directors, as she brings a wide range of strategy, product development, and marketing leadership expertise. Lisa’s breadth of experience in growing medical device businesses will be an incredible asset to NeuroPace as we continue to execute our commercial strategy,” said CEO, Mike Favet. 

The company also announced the resignation of Evan Norton from the Board, effective November 1, 2021.

About Lisa Andrade

Lisa Andrade is CEO of M33, an executive coaching and leadership development firm, which she founded in 2018. Before founding M33, she served as Chief Marketing Officer at St. Jude Medical, a global medical device company, which was acquired by Abbott in 2017. Ms. Andrade has held numerous executive leadership positions in engineering, research, product development, strategy, product management, marketing, healthcare economics, and sales. She has been instrumental in the development and commercialization of numerous innovative medical devices and software products in the healthcare market and has been awarded multiple patents.

“I am delighted to join the board of directors at NeuroPace to support their mission to transform the lives of patients suffering from epilepsy through its novel brain-responsive RNS® System, delivering personalized treatment to reduce or eliminate debilitating seizures,” commented Lisa Andrade. “In a therapy area primed for innovation, I look forward to contributing to the NeuroPace team as they establish a new standard of care and improve the quality of life for epilepsy patients around the world.”

Lisa Andrade received her B.S. in biomedical and electrical engineering and an M.S. in biomedical engineering from Duke University as well as an MBA from The Wharton School of Business at the University of Pennsylvania.

About NeuroPace, Inc.

Based in Mountain View, Calif., NeuroPace was founded to transform the lives of people living with epilepsy, a debilitating neurological disorder affecting approximately 1 in 26 people. In 2013, it introduced the RNS System, the first and only FDA-approved closed-loop, brain-responsive neuromodulation system that delivers truly personalized, data-driven treatment. In addition to treating drug-resistant focal epilepsy, long-term EEG data recorded by the RNS System is helping to advance scientific understanding of the human brain. The company’s brain-responsive neuromodulation technology holds the promise of treating additional neurological disorders that impact the quality of life for millions of people around the world.

For more information: https://www.neuropace.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team